@article{JTD3007,
author = {Qingli Jiao and Aiguo Wu and Guoli Shao and Haoyu Peng and Mengchuan Wang and Shufeng Ji and Peng Liu and Jian Zhang},
title = {The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers},
journal = {Journal of Thoracic Disease},
volume = {6},
number = {9},
year = {2014},
keywords = {},
abstract = {Triple negative breast cancer (TNBC) is one type of breast cancer (BC), which is defined as negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2). Its origins and development seem to be elusive. And for now, drugs like tamoxifen or trastuzumab which specifically apply to ER, PR or Her2 positive BC seem unforeseeable in TNBC clinical treatment. Due to its extreme malignancy, high recurrence rate and poor prognosis, a lot of work on the research of TNBC is needed. This review aims to summarize the latest findings in TNBC in risk factors, possible therapeutic targets and possible prognostic makers.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/3007}
}